Results 11 to 20 of about 69,642 (298)

An Atypical Local Vesicular Reaction to the Yellow Fever Vaccine [PDF]

Vaccines, 2017
Yellow fever vaccine is a live attenuated viral inoculation indicated for patients traveling to endemic areas. The vaccine is generally well tolerated with minimal adverse effects.
Robert H. Wauters, Camellia L. Hernandez, Maureen M. Petersen   +2 more
doaj   +2 more sources

Serious adverse event: late neurotropic disease associated with yellow fever vaccine [PDF]

Einstein (São Paulo), 2020
The yellow fever is a systemic disease that was under control due to the effective campaigns against the vector and promotion of vaccines programs. However, since 1999, outbreaks appeared because of inefficient control of the vector, and led to the need ...
Henrique Souza Barros de Oliveira, Patricia Padial de Araujo, Jamile Rafaela Poltronieri de Sousa, Ana Carolina Gariba Donis, Deise Moreira, Andrea Makssoudian   +5 more
doaj   +3 more sources

A qualitatively validated mathematical-computational model of the immune response to the yellow fever vaccine

BMC Immunology, 2018
Background Although a safe and effective yellow fever vaccine was developed more than 80 years ago, several issues regarding its use remain unclear. For example, what is the minimum dose that can provide immunity against the disease?
Carla R. B. Bonin, Guilherme C. Fernandes, Rodrigo W. dos Santos, Marcelo Lobosco   +3 more
doaj   +2 more sources

A YELLOW FEVER VACCINE [PDF]

BMJ, 1928
E. Hindle
openaire   +4 more sources

Midgut barriers prevent the replication and dissemination of the yellow fever vaccine inAedes aegypti [PDF]

bioRxiv, 2019
Background To be transmitted to vertebrate hosts via the saliva of their vectors, arthropod-borne viruses have to cross several barriers in the mosquito body, including the midgut infection and escape barriers.
Lucie Danet, Guillaume Beauclair, Michèle Berthet, Gonzalo Moratorio, Ségolène Gracias, Frédéric Tangy, Valérie Choumet, Nolwenn Jouvenet   +7 more
openalex   +2 more sources

Yellow fever vaccine-associated neurological disease: it is not just the silver generation at risk. [PDF]

BMJ Case Rep, 2019
A 35-year-old man presented to his optician with sudden onset diplopia and a 1-week history of headaches. He was noted to have sixth nerve palsy. The following day he was admitted to hospital with confusion and expressive dysphasia.
Goldstein EJ, Bell DJ, Gunson RN.
europepmc   +2 more sources

Pneumococcal conjugate vaccination schedules in infants—acquisition, immunogenicity, and pneumococcal conjugate and yellow fever vaccine co-administration study [PDF]

Trials, 2022
Background Pneumococcal conjugate vaccines (PCVs) effectively prevent pneumococcal disease, but the global impact of pneumococcal vaccination is hampered by its cost.
Grant A. Mackenzie, Isaac Osei, Rasheed Salaudeen, Ousman Secka, Umberto D’Alessandro, Ed Clarke, Jonas Schmidt-Chanasit, Paul V. Licciardi, Cattram Nguyen, Brian Greenwood, Kim Mulholland   +10 more
doaj   +2 more sources

Yellow Fever Vaccine

Emerging Infectious Diseases, 1999
Subhash C. Arya
doaj   +3 more sources

Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models.

Vaccine, 2021
Piras-Douce F, Raynal F, Raquin A, Girerd-Chambaz Y, Gautheron S, Sanchez MEN, Vangelisti M, Mantel N.   +7 more
europepmc   +2 more sources

Yellow fever vaccine: worthy friend or stealthy foe?

Expert Review of Vaccines, 2016
Recognition that the live yellow fever vaccine may rarely be associated with viscerotropic disease (YEL-AVD) has diminished its safety status. However, the vaccine remains the principal tool for limiting the occurrence of yellow fever, making large ...
Stephen Seligman, Jean‐Laurent Casanova   +1 more
openalex   +3 more sources